Cartesian Therapeutics Profit Margin

The latest profit margin for RNAC is -10422.48% as of June 2026. That compares with -3534.11% in the prior-year period — down 194.9% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Cartesian Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RNAC's profit margin moved from -3534.11% to -10422.48% — a 194.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cartesian Therapeutics's valuation or profitability profile.

Against Healthcare companies, RNAC currently prints -10422.48% for profit margin, while the sector average sits near 13.89%. That is roughly 75119.2% below the sector mean. Large gaps often invite a closer look at Cartesian Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Cartesian Therapeutics converts resources into returns. At -10422.48%, RNAC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -3534.11% in the prior-year period — down 194.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RNAC's profit margin (-10422.48%), review year-over-year change from -3534.11%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.